Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea flag South Korea · Delayed Price · Currency is KRW
37,250
-400 (-1.06%)
Last updated: Feb 26, 2026, 11:34 AM KST

Ildong Pharmaceutical Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,186,279328,764502,483764,721799,187449,542
Market Cap Growth
270.27%-34.57%-34.29%-4.31%77.78%18.46%
Enterprise Value
1,283,943467,886480,579872,139869,595531,687
Last Close Price
37650.0011770.0018160.0028550.0033600.0018900.00
PE Ratio
38.38-----
Forward PE
27.5914.7614.7614.7614.7614.76
PS Ratio
2.060.540.841.201.430.80
PB Ratio
5.071.982.803.754.791.77
P/TBV Ratio
5.682.483.754.967.372.08
P/FCF Ratio
177.7118.67---89.66
P/OCF Ratio
56.6711.62---23.21
PEG Ratio
-0.860.860.860.860.86
EV/Sales Ratio
2.230.760.801.371.550.95
EV/EBITDA Ratio
29.9212.52---16.02
EV/EBIT Ratio
67.9540.93---96.16
EV/FCF Ratio
192.3426.56---106.04
Debt / Equity Ratio
0.661.241.191.021.360.66
Debt / EBITDA Ratio
3.635.50---5.03
Debt / FCF Ratio
23.2811.67---33.28
Net Debt / Equity Ratio
0.410.730.730.630.430.32
Net Debt / EBITDA Ratio
2.243.23-5.24-2.92-2.852.43
Net Debt / FCF Ratio
14.336.85-2.64-1.97-2.7516.09
Asset Turnover
0.991.020.950.940.850.92
Inventory Turnover
3.764.424.234.443.974.07
Quick Ratio
0.480.520.410.440.590.74
Current Ratio
0.940.920.690.910.841.26
Return on Equity (ROE)
10.56%-7.17%-42.25%-76.68%-47.91%-5.13%
Return on Assets (ROA)
2.01%1.19%-5.27%-6.75%-5.17%0.57%
Return on Invested Capital (ROIC)
5.72%3.82%-16.60%-25.79%-18.97%1.67%
Return on Capital Employed (ROCE)
5.60%3.60%-19.80%-21.30%-15.50%1.30%
Earnings Yield
2.35%-1.39%-15.71%-18.52%-12.48%-2.90%
FCF Yield
0.56%5.36%-9.91%-8.55%-3.25%1.11%
Dividend Yield
0.55%-----
Payout Ratio
0.22%-----
Buyback Yield / Dilution
-2.17%-3.34%-2.61%-10.76%0.00%0.02%
Total Shareholder Return
-1.61%-3.34%-2.61%-10.76%0.00%0.02%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.